BibTex RIS Kaynak Göster

Günümüzde Sefalosporinler ve Antibiyotik Direnci

Yıl 2014, , 22 - 27, 01.01.2014

İsmail Yıldız Muhammet Ali Varkal Emin Ünüvar

https://doi.org/10.5222/j.child.2014.022

Öz

Sefalosporinler günümüzde yaygın olarak kullanılan bir antibiyotik grubudur. Birinci ve ikinci kuşlak sefalospo- rinlerin gram pozitif etkinlikleri fazla iken, üçüncü kuşak sefalosporinlerde gram negatif etkinlik hâkimdir. Sefalosporinler ayaktan parenteral tedavi prensiplerine de uygundur. Solunum yolu enfeksiyonları, üriner sistem enfeksiyonları, yumuşak doku enfeksiyonları, kemik ve iskelet sistemi enfeksiyonları, merkez sinir sistemi enfek- siyonları, bakteriyemi ve gonorede etkindir. Sefalosporinler bakterisidal, beta-laktamaza dirençli, vücut dokularına dağılımı iyi olan hem oral hem de parenteral kullanılabi- len ilaçlardır

Anahtar Kelimeler

Antibiyotik sefalosporin direnç

Kaynakça

  • 1. Liarrul LI, Testero SA, Fisher JF, Mobashery S. The future of β-lactams. Curr Opinion in Microbiol 2010;13:551-7. http://dx.doi.org/10.1016/j.mib.2010.09.008
  • 2. Bush K. Proliferation and significance of clinically relevant β-lactamases. Ann N Y Acad Sci 2013;1277:84-90.
  • 3. IOM (Institute of Medicine). Antibiotic resistance: Implications for global health and novel intervention strategies. Washington DC: The National Academies Press, 2010.
  • 4. Baguley D, Lim E, Bevan A, Pallet A, Faust SN. Prescribing for children - taste and palatability affect adherence to antibiotics: a review. Arch Dis Child 2012;97:293-7. http://dx.doi.org/10.1136/archdischild-2011-300909
  • 5. Bush K. Improving known classes of antibiotics: an optimistic approach for the future. Curr Opinion Pharmacol 2012; 12:527-34. http://dx.doi.org/10.1016/j.coph.2012.06.003
  • 6. Clavenna A, Bonati M. Differences in antibiotic prescribing in paediatrics outpatients. Arch Dis Child 2011;96:590-5. http://dx.doi.org/10.1136/adc.2010.183541
  • 7. Duncan DJA, Barr DA, Seaton RA. Outpatient parenteral antimicrobial therapy with ceftriaxone, a review. Int J Clin Pharmacol 2012;34:410-7. http://dx.doi.org/10.1007/s11096-012-9637-z
  • 8. Arslanköylü EA, Kuyucu S, Balcı S, Usta Y. İlk doz seftriakson sonrası anafilaksi. Türk Pediatri Arşivi 2011;46:81-3. http://dx.doi.org/10.4274/tpa.46.14
  • 9. Yao Y, Zhou RY, Wang Y. Fatal adverse effect of injected ceftriaxone sodium in China. Pharmacoepidemiology and Drug Safety 2012;21:1197-201. http://dx.doi.org/10.1002/pds.3232
  • 10. Seiffert SN, Hilty M, Perreten V, Endimiani A. Extendedspectrum cephalosporin- resistant gram-negative organisms in livestock: An emerging problem for human health. Drugs Resistance Updates 2013;16:22-45. http://dx.doi.org/10.1016/j.drup.2012.12.001
  • 11. Shlaes DM. New beta lactam, beta-lactamase inhibitor combinations in clinical development. Ann N Y Acad Sci 2013; 1277:105-14. http://dx.doi.org/10.1111/nyas.12010
  • 12. Uras G. Ülkemizdeki ilaç harcamaları. Milliyet Gazetesi, 5 Aralık 2013.
  • 13. Lodha R, Kabra SK, Pandey RM. Antibiotics for community- acquired pneumonia in children. Cochrane Database of Systematic Reviews 2013; Issue 6.
  • 14. Davey P, Brown E, Charani E, et al. Interventions to improve antibiotic prescribing practices for hospital inpatients (review). Cochrane Database of Systematic Reviews 2013; Issue 4.
  • 15. Hollis A, and Ahmad Z. Preserving antibiotics, rationally. N Engl J Med 2013;369:2474-6. http://dx.doi.org/10.1056/NEJMp1311479
  • 16. Scientific Advisory Group on Antimicrobials of the Committee for Medicinal Products for Veterinary Use. Reflection paper on the use of third and fourth generations cephalosporins in food producing animals in the European Union: Development of resistance and impact on human and animal health. J Vet Pharmacol Therap 2009;32:515-33.
  • 17. Zhanel GG, Lawson CD, Adam H, et al. Ceftazidimeavibactam: a novel cephalosporin/β-lactamase inhibitor combination. Grugs 2013;73:159-77. http://dx.doi.org/10.1007/s40265-013-0013-7
  • 18. Gündem NS, Çıkman A, Gülhan B. İdrar kültürlerinden izole edilen E. coli ve Klebsiella spp. suşlarının genişlemiş spektrumlu beta-laktamaz (GSBL) üretimi ve antibiyotik direnci. J Clin and Experiment Invest 2013;4:56-62. http://dx.doi.org/10.5799/ahinjs.01.2013.01.0234

Cephalosporin Antibiotics and Antibiotic Resistance in Daily Practice

Yıl 2014, , 22 - 27, 01.01.2014

İsmail Yıldız Muhammet Ali Varkal Emin Ünüvar

https://doi.org/10.5222/j.child.2014.022

Öz

Nowadays, cephalosporins are commonly used antibiotics in pediatrics. First and second- generation cephalosporins have been used for infectious diseases caused by gram posi- tive bacteria but third- generation cephalosporins are pre- ferred for gram negative bacterial infections. Cephalosporins are also suitable for outpatient parenteral treatment They are effective in respiratory tract infections, urinary system infections, soft tissue infections, skeletal infections, central nervous system infections, bacteremia, and gonorrhea. Cephalosporins can be used through both oral, and parente- ral routes. They are bactericidal, and resistant to β-lactamase with good distribution into tissues

Anahtar Kelimeler

Antibiotic cephalosporin resistance

Kaynakça

  • 1. Liarrul LI, Testero SA, Fisher JF, Mobashery S. The future of β-lactams. Curr Opinion in Microbiol 2010;13:551-7. http://dx.doi.org/10.1016/j.mib.2010.09.008
  • 2. Bush K. Proliferation and significance of clinically relevant β-lactamases. Ann N Y Acad Sci 2013;1277:84-90.
  • 3. IOM (Institute of Medicine). Antibiotic resistance: Implications for global health and novel intervention strategies. Washington DC: The National Academies Press, 2010.
  • 4. Baguley D, Lim E, Bevan A, Pallet A, Faust SN. Prescribing for children - taste and palatability affect adherence to antibiotics: a review. Arch Dis Child 2012;97:293-7. http://dx.doi.org/10.1136/archdischild-2011-300909
  • 5. Bush K. Improving known classes of antibiotics: an optimistic approach for the future. Curr Opinion Pharmacol 2012; 12:527-34. http://dx.doi.org/10.1016/j.coph.2012.06.003
  • 6. Clavenna A, Bonati M. Differences in antibiotic prescribing in paediatrics outpatients. Arch Dis Child 2011;96:590-5. http://dx.doi.org/10.1136/adc.2010.183541
  • 7. Duncan DJA, Barr DA, Seaton RA. Outpatient parenteral antimicrobial therapy with ceftriaxone, a review. Int J Clin Pharmacol 2012;34:410-7. http://dx.doi.org/10.1007/s11096-012-9637-z
  • 8. Arslanköylü EA, Kuyucu S, Balcı S, Usta Y. İlk doz seftriakson sonrası anafilaksi. Türk Pediatri Arşivi 2011;46:81-3. http://dx.doi.org/10.4274/tpa.46.14
  • 9. Yao Y, Zhou RY, Wang Y. Fatal adverse effect of injected ceftriaxone sodium in China. Pharmacoepidemiology and Drug Safety 2012;21:1197-201. http://dx.doi.org/10.1002/pds.3232
  • 10. Seiffert SN, Hilty M, Perreten V, Endimiani A. Extendedspectrum cephalosporin- resistant gram-negative organisms in livestock: An emerging problem for human health. Drugs Resistance Updates 2013;16:22-45. http://dx.doi.org/10.1016/j.drup.2012.12.001
  • 11. Shlaes DM. New beta lactam, beta-lactamase inhibitor combinations in clinical development. Ann N Y Acad Sci 2013; 1277:105-14. http://dx.doi.org/10.1111/nyas.12010
  • 12. Uras G. Ülkemizdeki ilaç harcamaları. Milliyet Gazetesi, 5 Aralık 2013.
  • 13. Lodha R, Kabra SK, Pandey RM. Antibiotics for community- acquired pneumonia in children. Cochrane Database of Systematic Reviews 2013; Issue 6.
  • 14. Davey P, Brown E, Charani E, et al. Interventions to improve antibiotic prescribing practices for hospital inpatients (review). Cochrane Database of Systematic Reviews 2013; Issue 4.
  • 15. Hollis A, and Ahmad Z. Preserving antibiotics, rationally. N Engl J Med 2013;369:2474-6. http://dx.doi.org/10.1056/NEJMp1311479
  • 16. Scientific Advisory Group on Antimicrobials of the Committee for Medicinal Products for Veterinary Use. Reflection paper on the use of third and fourth generations cephalosporins in food producing animals in the European Union: Development of resistance and impact on human and animal health. J Vet Pharmacol Therap 2009;32:515-33.
  • 17. Zhanel GG, Lawson CD, Adam H, et al. Ceftazidimeavibactam: a novel cephalosporin/β-lactamase inhibitor combination. Grugs 2013;73:159-77. http://dx.doi.org/10.1007/s40265-013-0013-7
  • 18. Gündem NS, Çıkman A, Gülhan B. İdrar kültürlerinden izole edilen E. coli ve Klebsiella spp. suşlarının genişlemiş spektrumlu beta-laktamaz (GSBL) üretimi ve antibiyotik direnci. J Clin and Experiment Invest 2013;4:56-62. http://dx.doi.org/10.5799/ahinjs.01.2013.01.0234
Toplam 18 adet kaynakça vardır.

Ayrıntılar

Birincil Dil Türkçe
Bölüm Araştırma Makaleleri
Yazarlar

İsmail Yıldız Bu kişi benim

Muhammet Ali Varkal Bu kişi benim

Emin Ünüvar Bu kişi benim

Yayımlanma Tarihi 1 Ocak 2014
Yayımlandığı Sayı Yıl 2014

Kaynak Göster

APA Yıldız, İ., Varkal, M. A., & Ünüvar, E. (2014). Günümüzde Sefalosporinler ve Antibiyotik Direnci. Journal of Child, 14(1), 22-27. https://doi.org/10.5222/j.child.2014.022
AMA Yıldız İ, Varkal MA, Ünüvar E. Günümüzde Sefalosporinler ve Antibiyotik Direnci. Journal of Child. Ocak 2014;14(1):22-27. doi:10.5222/j.child.2014.022
Chicago Yıldız, İsmail, Muhammet Ali Varkal, ve Emin Ünüvar. “Günümüzde Sefalosporinler Ve Antibiyotik Direnci”. Journal of Child 14, sy. 1 (Ocak 2014): 22-27. https://doi.org/10.5222/j.child.2014.022.
EndNote Yıldız İ, Varkal MA, Ünüvar E (01 Ocak 2014) Günümüzde Sefalosporinler ve Antibiyotik Direnci. Journal of Child 14 1 22–27.
IEEE İ. Yıldız, M. A. Varkal, ve E. Ünüvar, “Günümüzde Sefalosporinler ve Antibiyotik Direnci”, Journal of Child, c. 14, sy. 1, ss. 22–27, 2014, doi: 10.5222/j.child.2014.022.
ISNAD Yıldız, İsmail vd. “Günümüzde Sefalosporinler Ve Antibiyotik Direnci”. Journal of Child 14/1 (Ocak 2014), 22-27. https://doi.org/10.5222/j.child.2014.022.
JAMA Yıldız İ, Varkal MA, Ünüvar E. Günümüzde Sefalosporinler ve Antibiyotik Direnci. Journal of Child. 2014;14:22–27.
MLA Yıldız, İsmail vd. “Günümüzde Sefalosporinler Ve Antibiyotik Direnci”. Journal of Child, c. 14, sy. 1, 2014, ss. 22-27, doi:10.5222/j.child.2014.022.
Vancouver Yıldız İ, Varkal MA, Ünüvar E. Günümüzde Sefalosporinler ve Antibiyotik Direnci. Journal of Child. 2014;14(1):22-7.